Fourth School of Clinical Medicine, Zhejiang Chinese Medical University.
Department of Oncology, Affiliated Hangzhou First People's Hospital.
Am J Clin Oncol. 2022 May 1;45(5):223-231. doi: 10.1097/COC.0000000000000911. Epub 2022 Apr 14.
Pseudomyxoma peritonei is an infrequent solid tumor in clinical practice. The low morbidity and deficient understanding of this mucus-secreting malignant disease increase the risks of delayed identification or uncontrollable deterioration. In quite a lot cases, patients go through complete cytoreduction surgery and hyperthermic intraperitoneal chemotherapy could receive a long time survival over 5 years. But the recurrence rate is also hard to overlook. Unlike other types of cancer, the standard treatment for this considerable groups has not been confirmed yet. With the advanced medical progression, studies have been carrying out based on pathogenesis, biological characters, and mutated gene location. All but a few get statistical survival benefits, let alone the breaking progress on research or therapeutic practice in the field. We try to give a comprehensive exposition of pseudomyxoma peritonei around the epidemiology, radiologic features, clinical manifestation, present treatment and promising schemes, hoping to arise much attention and reflection on the feasible solutions, especially for the recrudescent part.
腹膜假黏液瘤是临床实践中一种罕见的实体肿瘤。这种分泌黏液的恶性疾病发病率低，人们对其认识不足，增加了其识别延迟或不可控恶化的风险。在很多情况下，患者接受了彻底的细胞减灭术和腹腔热灌注化疗，可获得超过 5 年的长期生存。但复发率也不容忽视。与其他类型的癌症不同，对于这一相当大的群体，其标准治疗尚未得到确认。随着医学的进步，已经基于发病机制、生物学特征和基因突变位置进行了研究。除了少数人获得了统计学上的生存获益外，在该领域的研究或治疗实践方面几乎没有取得突破性进展。我们试图围绕腹膜假黏液瘤的流行病学、影像学特征、临床表现、现有治疗方法和有前途的方案进行全面阐述，希望引起人们对可行解决方案的更多关注和思考，特别是对复发部分。
